With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technologyNEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intell ...

hyperliquid will have more equity derivative markets than crypto perps by Q4 2026 ...

Though the tariff situation remains uncertain, some bright spots have appeared. Initial trade agreements with the U.K. and China suggest levels may not be as high as initially expected. And Target's own efforts -- such as negotiating with vendors and adjusting product assortment -- could limit impact, too. Meanwhile, Target, recognizing its growth problem, took a big step to address it recently by creating an "enterprise acceleration office." This team's goal is to speed up progress along the path to growth ...

Upwork Inc. (UPWK) is starting to look more than just a place for quick freelance gigs. With its new Business Plus plan, the company is going after bigger clients—and it’s working. In the last reported quarter, the number of active clients on Business Plus more than doubled. About 40% of them are brand new to Upwork, which is impressive considering Upwork hasn’t even spent much on marketing the plan. That shows the offer is meeting a clear need.Business Plus gives clients a smoother hiring experience. They ...

BPH Market & Aquablation Therapy - Benign Prostatic Hyperplasia (BPH) affects approximately 40 million men in the U S [21] - The U S BPH surgical market represents a ~$20 billion opportunity [27] - Approximately 70% of prostates treated with Aquablation in the U S are less than 100ml in size [41] - Aquablation therapy provides effective, safe, and durable outcomes independent of prostate size, shape, and surgeon experience [36] Financial Performance & Guidance - Total revenue increased by 72% year-over-year to $24 4 million in Q1 2023 [51] - U S Aquabeam install base increased by 106% year-over-year to 192 systems in Q1 2023 [51] - U S handpieces sold increased by 139% year-over-year in Q1 2023 [51] - The company projects total revenue of $128 0 million for 2023, representing approximately 71% year-over-year growth [53, 54] - The company anticipates a gross margin of 54% for 2023 [54] Commercial Strategy & Expansion - The company is targeting 860 high-volume hospitals in the U S with an annual resective volume of ≥100 procedures [62] - 17 Strategic IDNs account for ~29% of BPH hospitals and ~26% of high-volume centers [70] - 65% of high volume hospitals are within a 100-mile radius of Robotic Sales Representatives [73]

Investor Event © 2024 PROCEPT BioRobotics Corporation. All Rights Reserved. Safe Harbor Statement This presentation and accompanying oral presentation contain "forw ard-looking statements" w ithin the meaning of the Private Securities Litigation Reform Act of 1995, including the ex pected financial results of PROCEPT BioRobotics Corporation (the "Company"). W ords such as "anticipates," "believes," "ex pects," "intends," "projects," "anticipates," and "f uture" or similar ex pressions are intended to identi ...

IT Solutions Provider Will Use VERSES' Genius Platform to Improve IT Workforce Scheduling and ProductivityVANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSD) ("VERSES" or the "Company"), a cognitive computing company specializing in next-generation agentic software systems, has signed Kalosys, an AI-driven IT solutions provider, as an enterprise customer. Kalosys plans to become a VERSES-certified Genius reseller. Kalosys helps organizations adopt and sc ...

大 类 资 产 配 置 相关研究 - 证券分析师 金倩婧 A0230513070004 jinqj@swsresearch.com 冯晓宇 A0230521080005 fengxy2@swsresearch.com 林遵东 A0230524100005 linzd@swsresearch.com 王胜 A0230511060001 wangsheng@swsresearch.com 研究支持 涂锦文 A0230123070009 tujw@swsresearch.com 联系人 涂锦文 (8621)23297818× tujw@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 2025 年 06 月 23 日 通胀预期升温，全球权益多数回调 ——全球资产配置每周聚焦 (20250614-20250620) 请务必仔细阅读正文之后的各项信息披露与声明 略 研 究 证 券 研 究 报 告 策 ⚫ 本周（20250614–20250620）。本周美联储维持利率不变符合市场预期，但是联储将今年个人消费支 出价格指数涨幅的预测中值从 3 月份的 2.7%升至 3%，显著高于美联储 2%的 ...

60 Minutes overtime. We always thought everything was good. We kept getting letters saying that they're increasing his payments. Then we get this letter saying we owe $51,000. This week on 60 Minutes, we take a look at what happens when Social Security overpays people who receive benefits. They can find out years and in some cases decades later that they owe thousands or tens of thousands of dollars. I'm Andy Court and I'm a producer at 60 Minutes. I'm Annabelle Hanfleig and I'm an associate producer at 60 ...

5月22日，聚水潭集团股份有限公司（下称"聚水潭"）递交招股书，再次报考在港交所上市。据贝多财经了解，聚水潭曾分别于2023年6月、2024年3月和 2024年11月递表，此次是"失效"后的又一次更新。 据贝多财经了解，聚水潭的主要经营主体为上海聚水潭网络科技有限公司。天眼查App信息显示，该公司成立于2014年9月，注册资本为1073.6172万元， 法定代表人为骆海东，全资股东为Hong Kong True Value Limited。 相较此前招股书，聚水潭更新了2024年度的财务数据等信息。根据招股书，聚水潭2022年、2023年和2024年的营收分别约人民币5.23亿元、6.97亿元和 9.10亿元。其中，2024年的营收增长率约为30.5%。 2022年、2023年和2024年，聚水潭的净利润分别约为-5.07亿元、-4.90亿元和1058.3万元。按非国际财务报告准则计量，聚水潭的经调整净利润分别约 为-3.79亿元、-2.06亿元和4898.8万元，于2024年实现扭亏为盈。 | | | | CITE TOTHT LIX | | | | | --- | --- | --- | --- | -- ...